Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses.
about
The relative efficacy of trivalent live attenuated and inactivated influenza vaccines in children and adultsEstimating influenza vaccine efficacy from challenge and community-based study dataInfluenza virus vaccines: lessons from the 2009 H1N1 pandemicInfluenza and Memory T Cells: How to Awake the ForceThe management of acute bronchitis in childrenSafety and immunogenicity following administration of a live, attenuated monovalent 2009 H1N1 influenza vaccine to children and adults in two randomized controlled trialsEvaluation of replication and cross-reactive antibody responses of H2 subtype influenza viruses in mice and ferrets.Avian influenza pandemic preparedness: developing prepandemic and pandemic vaccines against a moving targetPlasmid-only rescue of influenza A virus vaccine candidates.Evaluation of three live attenuated H2 pandemic influenza vaccine candidates in mice and ferrets.Adenovirus as a carrier for the development of influenza virus-free avian influenza vaccines.Current status of live attenuated influenza vaccine in the United States for seasonal and pandemic influenza.Influenza vaccines: from surveillance through production to protection.Flexible label-free quantitative assay for antibodies to influenza virus hemagglutininsA novel sequence-based antigenic distance measure for H1N1, with application to vaccine effectiveness and the selection of vaccine strainsAlkyl polyglycoside, a highly promising adjuvant in intranasal split influenza vaccines.Comparison of a live attenuated 2009 H1N1 vaccine with seasonal influenza vaccines against 2009 pandemic H1N1 virus infection in mice and ferrets.Meta-analysis of the immunogenicity and tolerability of pandemic influenza A 2009 (H1N1) vaccines.Current cell-based influenza vaccine production technology as pandemic contingency.Strategies to achieve the healthy people 2020 annual influenza vaccine coverage goal for health-care personnel: recommendations from the national vaccine advisory committee[Concepts, effectiveness, and perspectives of pandemic and seasonal influenza vaccines].Trivalent intranasal influenza vaccine, live.Serum-free microcarrier based production of replication deficient influenza vaccine candidate virus lacking NS1 using Vero cells.Influence of prior influenza vaccination on antibody and B-cell responses.Safety, efficacy, and immunogenicity of an inactivated influenza vaccine in healthy adults: a randomized, placebo-controlled trial over two influenza seasons.Single HA2 mutation increases the infectivity and immunogenicity of a live attenuated H5N1 intranasal influenza vaccine candidate lacking NS1.Safety, efficacy and effectiveness of cold-adapted, live, attenuated, trivalent, intranasal influenza vaccine in adults and children.School-located influenza vaccination decreases laboratory-confirmed influenza and improves school attendance.Can successful vaccines teach us how to induce efficient protective immune responses?Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP) -- United States, 2014-15 influenza season.The magnitude of local immunity in the lungs of mice induced by live attenuated influenza vaccines is determined by local viral replication and induction of cytokinesGenetic measurement of memory B-cell recall using antibody repertoire sequencing.The potential for a controlled human infection platform in Singapore.Live attenuated and inactivated influenza vaccines in childrenIntranasal delivery of Norwalk virus-like particles formulated in an in situ gelling, dry powder vaccine.Quantitative review of antibody response to inactivated seasonal influenza vaccines.Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines.Comparison of the influenza virus-specific effector and memory B-cell responses to immunization of children and adults with live attenuated or inactivated influenza virus vaccines.Cold-adapted, live attenuated influenza vaccine.Anti-influenza serum and mucosal antibody responses after administration of live attenuated or inactivated influenza vaccines to HIV-infected children.
P2860
Q24622008-FFD18453-96D3-4294-B11D-16EE7157853EQ24655781-E8549704-0DF6-488C-892D-756B28347A19Q27027029-A746AFCC-B554-490F-A555-5107B886BE91Q28070255-4FAFD259-91E6-41A5-9357-4700F82F19F5Q28288887-D3E86A6C-2F28-4837-B73E-C49F2A5E67B2Q28748654-E6EBAAFD-A931-45EE-BD91-30D4C21C2C4DQ30227151-CFF3083F-3AAB-4270-95BC-7C8AE43FB461Q30227194-46B5D13D-32DF-48A4-89DA-FEBF4A94502DQ30329368-3A290523-F5A8-4C21-B5BF-FAAD1A009619Q30357270-BBA564FA-5812-4068-94A4-F5C5C6A6F491Q30375982-8B627059-80C1-4D0C-9C51-23016C1031EAQ30377205-F90AC981-C03D-486F-8D5D-CB9BFE9CA972Q30385118-EA788957-F503-455F-BCEC-B3CC4D6E0506Q30391853-7B83D355-D4CA-44C9-B472-D7583BA2B11AQ30396902-8B3ABAF6-B793-45F2-80AF-8B74F99AC1B0Q30397973-4A13DD8C-4C49-4EE6-AE1A-65322CC19ACAQ30398879-0F69C2E5-EC2F-466D-B397-76BDF022D2C2Q30407050-45EF2851-5423-4403-B6FF-A27F4639B146Q30414391-BE59EC6C-AADA-4B18-A445-DA362AECD183Q30415584-EB5B3193-8EC2-49A3-9BDA-F01E52FB215EQ30425269-BBD799E3-AD06-444E-9E8E-28BC97BC0230Q30434868-5D1999BD-7D75-42C4-A861-2B994835C457Q30474419-CC039306-F2C2-475A-B075-EC5DED2AF099Q33361605-9AB26F15-6D9E-4DB1-8F6D-E7DCFF9E9E57Q33541763-48066D9D-D6CC-40C2-8C8A-80F3E5A9E639Q33872175-2705F750-A7D9-4732-802B-6CF09AD2728EQ34108101-35C393E1-D318-4112-9A56-2D5998023495Q34137789-924FD106-A1CD-4374-AA29-A78400FFBC7FQ34409182-CD47E03F-F481-445C-875E-2B0D19F8438AQ34433508-B056189A-B2DA-43F3-A5AE-8D9BD5E1E23EQ34458066-05749F8A-2431-4F1E-AA3F-21F257297042Q34880392-D1C1C9E4-6FB0-482A-BD7E-7BFE44806DCCQ34952265-C27BF17D-E3D5-47E4-AB90-0261440E5D91Q34974775-5A8C4FE4-E9C6-4FDF-94DF-FF767BB242A9Q35112676-2B31C0E8-42FD-4ECD-A47E-783E131D1C39Q35218808-6979E207-2D98-4C7C-BF25-6CA73A17D583Q35629114-CC73CDDB-C875-4F51-8EBF-29B21823778AQ35634295-54909086-E243-4CBD-9A6B-F02F649CA8FCQ35728567-F87FDC29-59B0-4E71-8753-808FE3D2D87AQ35789909-1E48A114-0C27-4718-8FF4-001970FCF787
P2860
Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses.
description
1999 nî lūn-bûn
@nan
1999 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Evaluation of trivalent, live, ...... 1N1), A (H3N2), and B viruses.
@ast
Evaluation of trivalent, live, ...... 1N1), A (H3N2), and B viruses.
@en
type
label
Evaluation of trivalent, live, ...... 1N1), A (H3N2), and B viruses.
@ast
Evaluation of trivalent, live, ...... 1N1), A (H3N2), and B viruses.
@en
prefLabel
Evaluation of trivalent, live, ...... 1N1), A (H3N2), and B viruses.
@ast
Evaluation of trivalent, live, ...... 1N1), A (H3N2), and B viruses.
@en
P2093
P1433
P1476
Evaluation of trivalent, live, ...... 1N1), A (H3N2), and B viruses.
@en
P2093
Treanor JJ
P304
P356
10.1016/S0264-410X(99)00334-5
P407
P577
1999-12-01T00:00:00Z